Results 191 to 200 of about 75,183 (262)

Long‐Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real‐World Analysis

eJHaem, Volume 6, Issue 6, December 2025.
ABSTRACT Introduction Ruxolitinib is a key therapeutic option for patients with myeloproliferative neoplasms. Its short‐term toxicity profile is well‐established, but long‐term safety data remains scarce. Methods We aimed to evaluate toxicity associated with long‐term exposure to ruxolitinib (defined as 3 years or longer) through a dual‐cohort ...
Alberto Blanco‐Sánchez, Rosa Ayala, Gonzalo Carreño‐Tarragona, Rafael Colmenares, Nieves López‐Muñoz, Adolfo Sáez, María Luisa Palacios‐Berraquero, Julia Hernández, Joaquín Martínez‐López   +8 more
wiley   +1 more source

Associations between health information source and childhood vaccination. [PDF]

Front Public Health
Geller KS, Montaine-O'Brien SJ, Branscum PW, Reeves-Doyle BN.   +3 more
europepmc   +1 more source

Effectiveness of the National Immunisation Programme and the catch-up vaccination on the incidence of hepatitis B in China: an interrupted time series analysis from 2005 to 2019. [PDF]

BMJ Glob Health
Ming BW, Zhang J, Li L, Xu X, Shi C, Zhang J, Ou CQ.   +6 more
europepmc   +1 more source

Optimising Vaccination Status in a Belgian Dermatological Immune‐Mediated Inflammatory Disease Population: An Education‐Based Pro‐Active Patient‐Centred Approach

JEADV Clinical Practice, Volume 4, Issue 5, Page 1033-1038, December 2025.
ABSTRACT Background Patients with dermatological immune mediated inflammatory diseases (IMIDs) are increasingly treated with immunosuppressive and ‐modulating drugs. Some of these drugs increase the risk of acquiring infections and more complications can arise during an infection while treated with these agents.
Femke Lieten, Tine Vanhoutvin, Dorien Hunin, Céline Vanvelk, Liesbeth Gilissen, Petra De Haes, An Van Laethem, Francisca Castelijns, Tom Hillary   +8 more
wiley   +1 more source

Comparative safety evaluation of pentavalent (DTaP-IPV-Hib) and hexavalent (DTaP-IPV-Hib-HepB) vaccines in infants: a real-world analysis based on VAERS. [PDF]

Front Cell Infect Microbiol
Wei Z, Li B, Jia HL.
europepmc   +1 more source

Modular Nanosensing Platforms for Tuberculosis and Beyond: Engineering Biomaterials Toward Cross‐Pathogen Diagnostic Universality

MedComm – Biomaterials and Applications, Volume 4, Issue 4, December 2025.
Modular nanosensing platforms utilize nanomaterials and functionalized interfaces to amplify trace different pathogens (like tuberculosis) antigen capture, suppress matrix interference, and enable multiplex detection. Their portability and cost‐effectiveness support rapid screening in resource‐limited settings and real‐time monitoring, advancing high ...
Mei Li, Yuxin Luo, Wenqiang Li, Yiqing Wang, Yunze Tai, Zhiping Deng, Yao Luo   +6 more
wiley   +1 more source

Immune Modulation Through Long‐Term Lacticaseibacillus rhamnosus Therapy in Home Mechanically Ventilated Patients

MicrobiologyOpen, Volume 14, Issue 6, December 2025.
Antibiotic resistance crisis drives the search for innovative antibacterial solutions. Probiotics, particularly Lacticaseibacillus rhamnosus GG ATCC 53103 (LGG), show promise in preventing bacterial infections and reducing antibiotic use. LGG has well‐documented health benefits and can strengthen the immune system, especially in chronically ill ...
Kamila Szyller, Grazyna Mlynarczyk, Beata Mlynarczyk‐Bonikowska, Janusz Sierdzinski, Joanna Styk, Michal Marusza, Wojciech Marusza   +6 more
wiley   +1 more source

Pharmacologic and Clinical Applications of Commonly Administered Medications to Neonates: Focus on Vitamin K, Vitamin D, and Hepatitis B Vaccine Un Updated Review

Mohammed Ali Khalifa, Youssef Mahdi
openalex   +2 more sources

Hepatitis B vaccination status and associated factors among people living with HIV in Gulu, Uganda: a cross-sectional study. [PDF]

BMC Public Health
Nakabuye M, Segawa I, Ojiambo KO, Ndagga GW, Ocama P, Byakika-Kibwika P.   +5 more
europepmc   +1 more source

Adaptive Evolution and Distinct Mutation Signatures of Full‐Length HBV Quasispecies in HBeAg‐Negative Chronic Hepatitis B

MicrobiologyOpen, Volume 14, Issue 6, December 2025.
HBeAg‐negative chronic hepatitis B harbors a highly heterogeneous HBV quasispecies shaped by region‐specific selection. Adaptive strategies underpinning viral persistence include: BCP/PreC mutations supporting replication, PreS/S mutations enabling immune evasion, and overlapping Pol/S mutations maintaining viral fitness.
Changhui Wu, Fengwei Liu, Xiao Li, Xiaojin Li, Hui Li, Sihang Zhang, Xiaohui Yan, Taicheng Zhou, Jia Wei   +8 more
wiley   +1 more source